

Figure S3 The dorsal imperfections in *net1* morphants is not resulted from MO injection-induced global defects in cell proliferation or survival. (A-B) Cell proliferation and survival

of the cMO or MO1 injected embryos. The embryos injected with 4 ng cMO or 4 ng *net1* MO1 were subjected to immunostaining with anti-pH3 antibody (red) (A) or Tunnel staining (red) (B). DAPI was used as a counterstain for cell nuclei (blue). Scale bar: 100 μm, shield and 75% epiboly stages; 200 μm, 24 hpf stage. (C) Morphological defects in *p53* mutants injected with *net1* MO1. Scale bar: 100 μm, shield stage; 200 μm, 24 hpf. (D) The expression of dorsal marker *boz* and *chd* at sphere stage in *p53*-/- mutants injected with cMO or *net1* MO1.